Complete Response Letter Final Rule

The Food and Drug Administration (FDA) is amending its regulations on new drug applications (NDAs) and abbreviated new drug applications (ANDAs) for approval to market new drugs and generic drugs (drugs for which approval is sought in an ANDA).  The final rule discontinues FDA’s use of approvable letters and not approvable letters when taking action on marketing applications.  Instead, we will send applicants a complete response letter to indicate that the review cycle for an application is complete and that the application is not ready for approval.  We are also revising the regulations on extending the review cycle due to the submission of an amendment to an unapproved application and starting a new review cycle after the resubmission of an application following receipt of a complete response letter.  In addition, we are adding to the regulations on biologics license applications (BLAs) provisions on the issuance of complete response letters to BLA applicants.  We are taking these actions to implement the user fee performance goals referenced in the Prescription Drug User Fee Amendments of 2002 (PDUFA III) that address procedures and establish target timeframes for reviewing human drug applications.

• Final Rule This link goes to Regulations.gov; to see the final rule, click on either the HTML or PDF icon under the "Views" column.
• FDA News: FDA Revises Process for Responding to Drug Applications
• Questions and Answers

Back to Top     Back to PDUFA

PDF requires the free Adobe Acrobat Reader

Date created: July 9, 2008, updated July 11, 2008

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA/Center for Drug Evaluation and Research